Theranexus Stock

Theranexus EBIT

The EBIT of Theranexus (ALTHX.PA) as of Aug 20, 2026 is -10.23 M EUR. In the previous year, EBIT was -4.81 M EUR — a change of 112.58% (lower).

EBIT

-10.23 MEUR

YoY

112.58%

Last updated:

In 2026, Theranexus's EBIT was -10.23 M EUR, a 112.58% increase from the -4.81 M EUR EBIT recorded in the previous year.

The Theranexus EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined EUR)
Date
EBIT (undefined EUR)
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
0.00 base
YEAREBIT (undefined EUR)
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
Access this data via the Eulerpool API

Theranexus Revenue

Theranexus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
563,851.00 EUR
-7.94 M EUR
-5.58 M EUR
Jan 1, 2020
294,609.00 EUR
-6.39 M EUR
-4.80 M EUR
Jan 1, 2021
602.00 EUR
-9.88 M EUR
-8.15 M EUR
Jan 1, 2022
414,898.00 EUR
-7.03 M EUR
-6.57 M EUR
Jan 1, 2023
296,331.00 EUR
-7.64 M EUR
-6.83 M EUR
Jan 1, 2024
2.28 M EUR
-4.81 M EUR
-1.77 M EUR
Jan 1, 2025
0.00 EUR
-10.23 M EUR
-3.00 M EUR
Jan 1, 2026 (e)
0.00 EUR
-7.00 M EUR
1.66 M EUR

Theranexus Margins

Theranexus stock margins

The Theranexus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Theranexus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Theranexus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
-1,196.20 %
-1,408.28 %
-989.58 %
Jan 1, 2020
-1,803.56 %
-2,170.21 %
-1,628.46 %
Jan 1, 2021
-1.47 M %
-1.64 M %
-1.35 M %
Jan 1, 2022
19.98 %
-1,694.99 %
-1,582.80 %
Jan 1, 2023
-1,565.37 %
-2,579.44 %
-2,304.16 %
Jan 1, 2024
-14.61 %
-210.66 %
-77.30 %
Jan 1, 2025
-14.61 %
- %
- %
Jan 1, 2026 (e)
-14.61 %
- %
- %

Theranexus Stock analysis

What does Theranexus do? Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Theranexus's EBIT

Theranexus's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Theranexus's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Theranexus's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Theranexus’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Theranexus stock

EBIT of Theranexus is -10.23 M EUR in 2026.

EBIT of Theranexus changed from -4.81 M EUR to -10.23 M EUR, representing a 112.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Theranexus since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Theranexus historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Theranexus

All Key Metrics — Theranexus